Chronic Hives Treatment: What Works When Antihistamines Don't
SaveHives that recur daily or near-daily for six weeks or more are called chronic urticaria. When OTC antihistamines are insufficient, prescription-strength antihistamines, add-on therapies, and — for persistent cases — the biologic omalizumab (Xolair) are effective options. An allergist or dermatologist manages ongoing treatment.
Last updated: July 2026History
What is chronic urticaria and why does it happen?
Urticaria — commonly called hives — are raised, itchy welts that appear when mast cells in the skin release histamine and other inflammatory mediators. When hives occur on most days for more than six weeks, they are classified as chronic urticaria. 1Ref 1Zuberbier T, et al. (2022).The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard
Chronic urticaria has two main subtypes: - Chronic spontaneous urticaria (CSU) — hives appear without a clear external trigger; in many cases, the immune system is misfiring - Chronic inducible urticaria — hives are triggered by a specific physical stimulus such as pressure, cold, heat, or exercise
In the vast majority of chronic spontaneous cases — over 80% — no specific allergen is ever identified. Certain medications (especially NSAIDs like ibuprofen), thyroid autoimmunity, and other autoimmune processes are sometimes associated. A thorough evaluation looks for treatable underlying causes. 1Ref 1Zuberbier T, et al. (2022).The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard2Ref 2Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. (2014).The diagnosis and management of acute and chronic urticaria: 2014 update.Diagnostic evaluation for chronic urticaria; role of allergist evaluation; omalizumab for antihistamine-refractory cases
Why might antihistamines stop working — or not work well enough?
Over-the-counter antihistamines (cetirizine, loratadine, fexofenadine) at standard doses are the first step. 1Ref 1Zuberbier T, et al. (2022).The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard For chronic urticaria, clinicians often:
- Increase the dose — using up to four times the standard dose of a second-generation antihistamine, which guidelines support as safe and more effective for some patients 1Ref 1Zuberbier T, et al. (2022).The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard
- Add a second antihistamine — combining agents
- Add an H2 antihistamine — famotidine (Pepcid) or ranitidine target a different histamine receptor and may add modest benefit when combined with H1 antihistamines
If higher-dose antihistamines still don't control the hives after 2–4 weeks, the next step is typically a specialist referral rather than continuing to try OTC options.
What prescription options exist for chronic hives?
Omalizumab (Xolair) is the most well-supported add-on treatment for chronic spontaneous urticaria that doesn't respond to antihistamines. 1Ref 1Zuberbier T, et al. (2022).The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard2Ref 2Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. (2014).The diagnosis and management of acute and chronic urticaria: 2014 update.Diagnostic evaluation for chronic urticaria; role of allergist evaluation; omalizumab for antihistamine-refractory cases It is a biologic injection given monthly that reduces the sensitivity of mast cells by binding free IgE. In a landmark randomized controlled trial (the ASTERIA study), the 300-mg omalizumab group achieved a mean weekly itch-severity score reduction of −9.8 versus −5.1 for placebo (P<0.001), with a substantial proportion achieving complete or near-complete control. 3Ref 3Maurer M, Rosén K, Hsieh HJ, et al. (2013).Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.Landmark RCT (ASTERIA): omalizumab 300 mg achieved a mean itch-severity score reduction of −9.8 vs −5.1 for placebo (P<0.001) in chronic spontaneous urticaria unresponsive to antihistamines It is now the standard second-line treatment in international guidelines. 1Ref 1Zuberbier T, et al. (2022).The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard
Cyclosporine is an immunosuppressant used in cases that don't respond to omalizumab. It has a more significant side effect profile requiring close monitoring and is generally reserved for refractory cases.
Short courses of oral corticosteroids (prednisone) can provide temporary relief during severe flares but are not appropriate for long-term management due to side effects.
Montelukast (a leukotriene modifier) is sometimes used as add-on therapy, though evidence is limited compared to omalizumab.
Should I see an allergist or a dermatologist for chronic hives?
Both allergists and dermatologists treat chronic urticaria. Your choice may depend on who your primary care clinician can refer you to, and whether an allergic cause is suspected.
- Allergists evaluate whether an underlying allergic trigger, food sensitivity, drug reaction, or autoimmune process is contributing; they are also most familiar with omalizumab and other biologics
- Dermatologists manage the skin manifestations and may be the appropriate specialist if an autoimmune skin condition is also a concern
A Gale primary care clinician can make the initial assessment, order baseline labs (CBC, thyroid function, inflammation markers) to check for common associated conditions, and coordinate the specialist referral. 2Ref 2Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. (2014).The diagnosis and management of acute and chronic urticaria: 2014 update.Diagnostic evaluation for chronic urticaria; role of allergist evaluation; omalizumab for antihistamine-refractory cases
What should I track before my specialist appointment?
Keeping a symptom diary helps significantly: - When hives appear and how long they last - Where on the body they occur - Any foods, medications, or supplements taken in the hours before - Physical triggers noticed (pressure, exercise, cold, heat) - Any associated throat swelling or breathing changes (angioedema — important to report immediately) - Antihistamines tried, at what doses, and what effect they had
Bringing this record to a specialist appointment makes the evaluation much more efficient. Apps and simple written logs are both effective.
Common questions
Related
Allergies & asthma
Xolair for Chronic Hives: Cost and Insurance CoverageAllergies & asthma
Hives All Over Body: Causes, Types & TreatmentAllergies & asthma
Biologic Medications for Severe Asthma: What to Know
Deciding about this?
A short, sourced overview to weigh with your clinician:
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
When chronic hives require urgent or emergency care
- —Swelling of the throat, tongue, or lips (angioedema affecting the airway) — call 911
- —Difficulty swallowing or speaking — call 911
- —Shortness of breath or chest tightness with hives — call 911
- —Hives with dizziness, fainting, or rapid heartbeat — seek emergency care
- —Facial or throat swelling even without breathing difficulty — seek same-day evaluation
Call 911 for any throat swelling, difficulty breathing, or fainting with hives.
This article provides general health education. Chronic urticaria diagnosis and treatment require assessment by a clinician or specialist. Do not adjust prescription medications without guidance from your provider.
Did this answer your question?
References
- 1.Zuberbier T, et al. (2022). The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. doi:10.1111/all.15090 ✓Classification of chronic urticaria, 6-week threshold definition, step-up treatment ladder including high-dose antihistamines and omalizumab as second-line standard
- 2.Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology. doi:10.1016/j.jaci.2014.02.036 ✓Diagnostic evaluation for chronic urticaria; role of allergist evaluation; omalizumab for antihistamine-refractory cases
- 3.Maurer M, Rosén K, Hsieh HJ, et al. (2013). Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New England Journal of Medicine. doi:10.1056/NEJMoa1215372 ✓Landmark RCT (ASTERIA): omalizumab 300 mg achieved a mean itch-severity score reduction of −9.8 vs −5.1 for placebo (P<0.001) in chronic spontaneous urticaria unresponsive to antihistamines
3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy